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Abstract
Background: Clinical studies have shown antineoplastic effectiveness of monoclonal antibodies (MAbs) against
EGFR for different indications. Several MAbs directed to EGFR were developed recently, such as matuzumab, but
there is still lack of information on preclinical data on its combination with chemo-radiation. Thus, the present
study intended to examine the molecular pathways triggered by matuzumab alone or associated to chemo-
radiotherapy in gynecological cell lines and its impact on cell growth and signaling.
Results: Combination of matuzumab with radiation and cisplatin did not enhance its cytostatic effects on A431,
Caski and C33A cells (high, intermediate and low EGFR expression, respectively) in clonogenic assays, when
compared to controls. The lack of effect was mediated by persistent signaling through EGFR due to its impaired
degradation. In spite of the fact that matuzumab inhibited phosphorylation of EGFR, it had no effect upon cell
viability. To analyze which downstream molecules would be involved in the EGFR signaling in the presence of
matuzumab, we have tested it in combination with either PD98059 (MAPK inhibitor), or LY294002 (PI3K inhibitor).
Matuzumab exhibited a synergic effect with LY294002, leading to a reduction of Akt phosphorylation that was
followed by a decrease in A431 and Caski cells survival. The combination of PD98059 and matuzumab did not
show the same effect suggesting that PI3K is an important effector of EGFR signaling in matuzumab-treated cells.
Nonetheless, matuzumab induced ADCC in Caski cells, but not in the C33A cell line, suggesting that its potential
therapeutic effects in vitro are indeed dependent on EGFR expression.
Conclusions: Matuzumab combined with chemoradiation did not induce cytotoxic effects on gynecological cancer
cell lines in vitro, most likely due to impaired EGFR degradation. However, a combination of matuzumab and PI3K
inhibitor synergistically inhibited pAkt and cell survival, suggesting that the use of PI3K/Akt inhibitors could overcome
intrinsic resistance to matuzumab in vitro. Altogether, data presented here can pave the way to a rational design of
clinical strategies in patients with resistant profile to anti-EGFR inhibitors based on combination therapy.
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Introduction
Epidermal growth factor receptor (EGFR), a 170-kDa
transmembrane glycoprotein, belongs to the ErbB/HER
family of receptors which includes HER2 (ErbB2/neu),
HER3 (ErbB3) and HER4 (ErbB4). Ligand binding leads
to the formation of homo or heterodimers between
members of the family, facilitating receptor autopho-
sphorylation. Phosphorylated receptors subsequently
activate signaling pathways that regulate cell prolifera-
tion, survival and transformation [1,2]. EGFR inhibition
by anti-EGFR monoclonal antibodies (MAbs) or tyrosine
kinase inhibitors (TKIs) represents a particularly suc-
cessful molecular targeted therapy for tumors such as
Non-Small Cell Lung Cancer and Colorectal Cancer.
Anti-EGFR MAbs bind EGFR with higher affinity than
the original ligands, preventing receptor activation.
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dation, with consequent cell cycle arrest, inhibition of
proliferation and angiogenesis, and promotion of in
vitro and in vivo antibody-dependent cellular cytotoxi-
city (ADCC) [3]. Although exhibiting a plethora of anti-
neoplastic mechanisms, numerous reports have
described that several patients using EGFR inhibitors
experience an initial clinical response followed by dis-
ease progression [4,5]. In spite of the benefits experi-
enced by most patients bearing EGFR mutations, some
of them will already present intrinsic resistance to
EGFR-targeted therapy at diagnosis.
Recently, several studies have shed light upon the
mechanisms of acquired resistance to anti-EGFR MAbs
and TKIs, and among them, the most important are the
incidence of EGFR mutations [6,7], altered mechanisms
of internalization and down-regulation of EGFR [6-8],
inability of MAbs to prevent the formation of ligand-
induced heterodimers [4], KRAS mutations [9] and
PTEN loss [4]. These mechanisms culminate in a sus-
tained activation of major intracellular signaling path-
ways controlled by MAPK and Akt, leading to persistent
cell survival [10]. Altogether, data suggest that altered
signal transduction emerges as a major driving force in
molecular target drug resistance and, therefore, one can
expect that resistance could be overpowered by the
combined use of specific inhibitors targeting such path-
ways in cancer cells.
Matuzumab, a humanized IgG1 derived from the mur-
ine precursor EMD 55900 (MAb 425), binds to EGFR
with high affinity [11] and, to the best of our knowledge,
data on the combination of matuzumab plus chemora-
diation are lacking. In this study, we sought to analyze
the effects of matuzumab, either alone or combined
with cisplatin and/or radiotherapy, on gynecological epi-
dermoid carcinoma cell lines expressing distinct EGFR
protein levels [12]. Here we show that matuzumab com-
bined with chemoradiation did not enhance cytotoxic
effects on gynecological cancer cells lines. In spite of
inhibiting autophosphorylation, matuzumab was not
able to induce EGFR down-regulation and persistent
activation of downstream signaling pathways was
observed. Accordingly, we analyzed the activation of
downstream targets of EGFR to determine the partners
involved in the signaling pathway elicited by EGF in the
matuzumab-treated cells. In this setting, PI3K/Akt path-
way inhibition, unlikely MAPK inhibition, sensitizes
gynecological cancer cells to matuzumab treatment in
vitro. These results reinforce the paradigm that several
signal transduction pathways control tumor growth and
contribute to resistance. Therefore, future therapeutic
approaches are likely to involve the combination of dif-
ferent antineoplastic targeted agents.
Materials and methods
Cell lines
A431 human cell line (vulvar carcinoma) was kindly
provided by Dr. Giuseppe Giaccone (University Hospital
Vrije Universiteit, The Netherlands). Caski and C33A
human cells (cervical carcin o m a )w e r ep r o v i d e db yD r .
Luisa L. Villa (Ludwig Institute for Cancer Research, SP,
Brazil).
Chemicals
Matuzumab and cetuximab were generously provided by
Merck KGaA (Darmstadt, Germany). PD98059,
LY294002 and MG132 were purchased from Calbio-
chem (Nottingham, UK).
Analysis of EGFR cell surface expression by flow
cytometry
As previously described [13], cells were incubated either
with a murine anti-EGFR Mab (0.1 μg/uL, BD Pharmin-
gen, San Diego, CA) or matuzumab (0.1 μg/uL) for 1 h
on ice. After washing, secondary antibodies (Caltag
Laboratories, Burlingame, CA) were added and samples
were analyzed on a FACScalibur using CELLQuest soft-
ware (Becton Dickinson, San Jose, CA).
MTT and clonogenic assays (CA)
For the MTT (3-(4,5-dimethythiazol-2-yl)-2,5-diphenyl-
tetrazolium bromide) assay, Caski and C33A cells were
incubated with matuzumab at different concentrations,
or matuzumab in the presence/absence of 25 μMo f
PD98059, a MEK1/2 inhibitor [14]. To compare matu-
zumab with cetuximab effects, A431, Caski and C33A
cells were incubated with 100 μg/mL of either antibody.
After 72 h, cells were incubated with a solution of MTT
(Sigma, St. Louis-MO), processed as previously
described [15]. Cell viability was expressed as a percen-
tage of controls (%CT).
For the combination experiments in CA, A431, Caski
and C33A cells were incubated with matuzumab (100
μg/mL) and LY294002 (10 μM) during the whole colony
formation assay. Alternatively, matuzumab (100 μg/mL)
and cisplatin (1.0, 0.5 and 0.15 μM for A431, Caski and
C33A cells, respectively) were added and cells were irra-
diated 6 h later (2.0, 1.5 and 0.3 Gy for A431, Caski and
C33A cells, respectively) with a
60Co-THERATRON-
780C irradiator (Theratronics, Canada), and maintained
at 37°C for 72 h. Each cell line was irradiated at differ-
ent intensities and also treated with different doses of
cisplatin according to the specific sensitivities of each
cell line, as previously described [12]. For experiments
comparing matuzumab to cetuximab, cells were incu-
bated with 100 μg/mL of either antibody for 72 h. Cells
were then kept in fresh medium for 10 days and the
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let was expressed as the surviving fraction (SF), pro-
cessed as previously described [13].
Cell cycle analysis
Cells were incubated in the presence of matuzumab
(100 μg/mL), as previously described [10]. After 24 h,
cell cycle phase distribution was analyzed by flow cyto-
metry using propidium iodide (PI) staining and the
resulting DNA content was analyzed on a Becton Dick-
inson FACScalibur using ModFitLT V2.0 software (Bec-
ton Dickinson, San Jose, CA).
Western blotting (WB) analysis
Cells were maintained in culture medium containing
10% FBS v/v and prior to MAb treatments and were
starved for 18 h in culture medium supplemented with
1% FBS v/v. Low serum concentration was used to
reduce signaling elicited by growth factors in the serum,
while ensuring survival of cells [16]. Prior to growth fac-
tor stimulation, cells were incubated for a period of 4 h
in serum-free medium in the presence of matuzumab
(100 μg/mL) alone or followed by a 15-minutes incuba-
tion with EGF (10 ng/mL) as previously described [13].
For combination experiments, cells were treated as
described above, plus 1 h of incubation with either
PD98059 (25 μM) or LY294002 (10 μM), alone or com-
bined with matuzumab before the incubation with EGF.
For EGFR degradation analysis, as described by others
[17], A431 and Caski cells were incubated with either
matuzumab or cetuximab (100 μg/mL, each) for 24 h in
serum-free culture medium and when indicated in the
figure, 15 μM of MG 132 (a proteasome inhibitor) was
added for the last 6 h in combination with either MAb.
Primary antibodies against total and phosphorylated
EGFR, HER2, Akt and MAPK (all from Cell Signaling
Technology, Beverly, MA, USA) were used. Immuno-
blots were developed using the enhanced chemolumi-
nescence (ECL) reagent (GE Health Care, SP, Brazil)
and bands were quantified with Labworks, version 4.6
(Bio-Rad, USA).
Annexin V staining
Cells were incubated in the presence of matuzumab
(100 μg/mL) or/and LY 294002 (10 μM). After 72 h,
apoptosis was analyzed by flow cytometry using annexin
V staining (BD Biosciences) on a Becton Dickinson
FACScalibur (Becton Dickinson, San Jose, CA).
In vitro ADCC assay
ADCC assay was performed with the kit CytoTox96
®
Non-Radioactive Cytotoxicity Assay (Promega, Madison,
WI). Cells were incubated alone or in the presence of 4
μg/mL of matuzumab for 4 h and exposed to peripheral
blood mononuclear cells (PBMC, effector cells) at effec-
tor/target ratio (E/T) of 20:1 for 4 h and specific cytoly-
sis (ADCC) was measured as previously described [13].
Statistical analysis
All experiments were performed in triplicates and the
values represent an average of at least 3 independent
experiments. Statistical analyses were performed using
GraphPad Prism 3.0 (GraphPad Software Incorporated,
San Diego, CA, USA). Quantitative experiments were
analyzed by Student’s t test. One-Way analysis of var-
iance (ANOVA) with Tukey’s post test was used to ana-
lyze the combination of matuzumab, cisplatin and RxT
versus double or individual treatments by CA. All P
values resulted from the use of two-sided tests and were
considered significant when < 0.05 or < 0.0001.
Results
A431, Caski and C33A cells differentially express EGFR
Previously, we have shown by Real Time PCR analysis
that A431 cells exhibit abnormally high expression of
EGFR, Caski cells express intermediate levels of EGFR
mRNA, whereas C33A cells express the lowest levels of
such molecule [12]. To further characterize the expres-
sion of EGFR in these cells, we have examined cell sur-
face EGFR expression by FACS and observed that both
a murine anti-EGFR MAb and matuzumab were able to
detect elevated, intermediate and low levels of mem-
brane-bound EGFR on A431, Caski and C33A cells,
respectively (Figure 1A).
Matuzumab does not inhibit cervical cancer cell
proliferation
In a previous study, we have demonstrated that matuzu-
mab was not able to inhibit A431 cells proliferation, nor
it caused significant changes in cell cycle distribution
[13]. In the present study, we also observed that matu-
zumab treatment did not decrease viability of cervical
cancer (CC) Caski and C33A cells accessed by MTT
assay, regardless of the concentration used (Figure 1B).
Also, there was no effect upon cell population distribu-
tion among the cell cycle phases in Caski and C33A
cells when compared to controls (Figure 1C).
Matuzumab did not sensitize A431, Caski and C33A cells
to chemo/radiotherapy
We evaluated whether the combination of matuzumab
(100 μg/mL) and radiotherapy (RxT) and/or cisplatin
could enhance the cytotoxic effects observed with the
isolated treatments on the A431, Caski and C33A cells.
Cisplatin and RxT either alone or combined decreased
the survival of all cell lines tested (P >0 . 0 5 ,F i g u r e1 D ) .
However, the combination of matuzumab with either
RxT or cisplatin was not able to enhance the cytotoxic
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combination of matuzumab, RxT and cisplatin was able
to enhance the cytotoxicity of combined treatment with
cisplatin and RxT (Figure 1D).
Matuzumab inhibits EGFR and HER2 phosphorylation
As matuzumab did not exert any effects on cell prolif-
eration of the gynecological cancer cell lines tested
(Figure 1 and reference 13), we sought to analyze the
phosphorylation state of EGFR receptor, as it ultimately
dictates its activation status. EGFR phosphorylation was
analyzed by WB in cells treated with matuzumab alone
(100 μg/mL) or in the presence of EGF. Receptor phos-
phorylation was increased by EGF treatment in A431
and Caski cells, while matuzumab strongly inhibited it
at least in 3 out of the four residues analyzed (Figure 2).
Figure 1 Matuzumab fails to induce chemo/radio sensitization of A431, Caski and C33A gynecological cancer cell lines.( A )E G F R
expression detected by Matuzumab on FACS analysis of A431, Caski and C33A cells, Student’s t test * P < 0.05, when compared to controls. (B)
Effects of matuzumab treatment (100 μg/mL) in Caski and C33A cells by MTT assay and (C) on cell cycle phase distribution analysis by flow
cytometry. (D) Effects of matuzumab alone (100 μg/mL) or combined with cisplatin (1.0, 0.5 and 0.15 μM for A431, Caski and C33A cells,
respectively) and/or RxT on colony formation by clonogenic assay (CA). One-Way ANOVA analysis of variance with Tukey’s post test * P < 0.05,
when compared to control cells.
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of EGFR in these cell lines, whereas matuzumab did not
(Figure 2). EGFR can interact with another member of
the ErbB family, HER2, an orphan receptor, to form het-
erodimers that are very potent in activating signal trans-
duction pathways [1]. Following matuzumab treatment,
there were no changes in total HER2 expression in
A431, Caski and C33A cell lines, however, EGF-induced
HER2 phosphorylation was inhibited by matuzumab in
A431 and Caski cell lines (Figure 2). Interestingly, in
C33A cells, that do express HER2 but not EGFR [12],
matuzumab treatment induced a slight reduction of
EGF-induced HER2 phosphorylation (Figure 2).
Matuzumab fails to inhibit Akt and ERK 1/2
phosphorylation elicited by EGF
Matuzumab treatment did not affect the overall expres-
sion of Akt and MAPK in the gynecological cancer cell
Figure 2 Matuzumab inhibits EGFR and HER2 phosphorylation, but not Akt and MAPK phosphorylation elicited by EGF.E f f e c t so f
Matuzumab (100 μg/mL) on EGF-induced activation of EGFR (Tyr 845, 992, 1045 and 1068), HER-2/neu, Akt and ERK 1/2 on A431, Caski and
C33A cells, detected by Western blotting.
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tion was increased by EGF treatment in A431 and Caski
cells, but not in C33A cells. There were no changes in
the phosphorylation state of the above mentioned
kinases when cells were treated with EGF in the pre-
sence of matuzumab (Figure 2). Altogether, these data
suggest that persistent signaling through the Akt and
MAPK pathways, even in the presence of matuzumab,
lead to increased survival of Caski and C33A cells, cor-
roborating the results obtained in the MTT assay and
cell cycle analysis (Figure 1).
Matuzumab does not induce EGFR down-regulation
Endocytosis and receptor degradation induced by anti-
EGFR MAbs culminate in the inactivation of growth
factor receptors and suppression of downstream signal-
ing pathways, reducing the proliferative/survival poten-
tial of cancer cells [3,17,18]. As the anti-EGFR MAb
cetuximab efficiently induces EGFR degradation [8,17]
and subsequent decrease cell survival [3,12], it was used
as a positive control to investigate if matuzumab could
induce EGFR down-regulation. A431 and Caski cells
were treated with either matuzumab or cetuximab (100
μg/mL) for 24 h. C33A cells were not included in this
experiment, since its EGFR expression is nearly unde-
tectable by WB. As expected, 24 h-treatment with
cetuximab induced a robust reduction of 50% and 70%
in EGFR protein content in A431 and Caski cells,
respectively (Figure 3A). As a proof of concept, we have
treated A431 cells with MG132, a proteassomal inhibi-
tor, and observed that EGFR accumulates both in its
total (Figure 3C) and in its phosphorylated form (Figure
3D), and a shift in the EGFR band is observed, probably
due to the increase in molecular weight caused by con-
jugation of ubiquitin molecules to the receptor (indi-
cated by the arrow in Figure 3C). The same result was
observed in Caski cells (data not shown). pEGFR accu-
mulation induced an increase both in pERK and pAkt,
implicating EGFR accumulation in the persistent activa-
tion of cell signaling pathways elicited by this receptor
(Figure 3D), however cetuximab only inhibited pERK
increase but not pAkt increase in the presence of pro-
teassomal inhibitor in both cells. In contrast, treatment
with matuzumab for 24 h failed to induce EGFR down-
regulation in both cell lines (Figure 3A), demonstrating
that this event is independent of the cell type analyzed
(as stated previously, Caski is a cervical carcinoma and
A431 is a vulvar carcinoma). Of note, the lack of EGFR
down-regulation after 24 h of matuzumab treatment
could explain the sustained cell proliferation and survi-
val observed in the cell cycle analysis, MTT and CA
assays (Figures 1 and 3B).
Combination of matuzumab with PD98059, a MAPK
inhibitor, induces antagonistic effects in A431, Caski and
C33A cells
A major signaling route of EGFR is the mitogen-acti-
vated protein kinases (MAPK) pathway and its overacti-
vation plays a critical role in tumor development and
progression [14]. Since we observed that matuzumab
could not reduce MAPK phosphorylation elicited by
EGF (Figure 2), we speculated that combination of
matuzumab and PD98059, a specific MEK1/2 inhibitor,
could decrease cell viability over single-drug treatments.
Although PD98059 treatment alone decreased cell viabi-
lity and ERK 1/2 phosphorylation of Caski and C33A
cells, isolated matuzumab did not (Figures 4A and 4B).
Surprisingly, there was no significant statistical differ-
ence between isolated and combined treatments in
C a s k ia n dC 3 3 Ac e l ls u r v i v a l( F i g u r e4 A ) ,w i t hn o
further decrease in ERK 1/2 phosphorylation status of
combined over single drug exposure (Figure 4B). We
have previously shown that matuzumab and PD98059
failed to cooperate in reducing the cell viability of A431
cells [13]. These results reinforce the idea that matuzu-
mab effects upon phosphorylation of EGFR, but not
EGFR degradation, are not modulating the persistent
MAPK signaling. This might be due to the fact that
EGFR phosphorylation is not completely abolished by
matuzumab and since the receptor is not degraded by
the MAb, matuzumab continues inducing cell signaling
and sustaining cell proliferation.
Blockade of Akt signaling is a determinant factor to
overcome resistance to matuzumab
Previous results of our group showed that when in com-
bination to cetuximab, that triggered EGFR degradation,
matuzumab induced further reduction in cell signaling
and survival when compared to cetuximab alone [13].
These results implicate that matuzumab binding to
EGFR induces distinct inhibitory effect to the ones
induced by cetuximab. Additionally, several reports have
described that the PI3K/Akt pathway remained active
and was involved in the lack of sensitivity to EGFR inhi-
bitors in different cell types [5,10,19]. Since diverse sig-
nal transduction pathways control tumor resistance to
antineoplastic agents, we hypothesized that, unlikely the
MAPK inhibitor PD98059, a PI3K-Akt pathway inhibitor
could decrease cell survival in the presence of matuzu-
mab. Based on this assumption, we investigated whether
the use of LY294002, a phosphatidylinositol 3-kinase
(PI3K) inhibitor, could overpower resistance to matuzu-
mab in vitro. As predicted, combined treatments
strongly reduced A431 and Caski cell survival (92% and
98% of inhibition, respectively) leading to a markedly
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Page 6 of 13Figure 3 Differences between matuzumab and cetuximab regarding the modulation of EGFR down-regulation, cell proliferation and
survival. (A) A431 and Caski cells were incubated with matuzumab or cetuximab (100 μg/mL, each) for 24 h in serum-free culture medium and
cells were then lysed for Western blotting analysis of total EGFR. (B) Effects of matuzumab or cetuximab (100 μg/mL, each) on cell metabolic
viability (MTT assay) and colony formation (clonogenic assay) of A431, Caski and C33A cells. Student’s t test * P < 0.05, when compared to
control cells. (C) Effects of MG132 (15 μM), a proteassomal inhibitor, in combination with cetuximab or matuzumab (100 μg/mL, each) on EGFR
expression of A431 cells, detected by Western blotting. (D) Effects of MG132 (15 μM) in combination with cetuximab (100 μg/mL) on
phosphorylation of EGFR (Tyr 1068), Akt and ERK1/2 on A431 and Caski cells, detected by Western blotting.
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nies (P <0 . 0 5a n dP < 0.0001, respectively) when com-
pared to either treatments alone (Figures 5A and 5B).
Additionally, the combination of LY294002 and matuzu-
mab in A431 and Caski cells was accompanied by a
markedly reduction of Akt phosphorylation, with no
changes in total Akt protein expression (Figure 5C).
In contrast, we have demonstrated that the combina-
tion of cetuximab and PD153035 (a specific EGFR TKI)
proved to be antagonistic in C33A cell line, with no
reduction in proliferation and EGFR, HER2, AKT and
MAPK phosphorylation status when compared to either
drug alone [12]. Previously, we demonstrated that C33A
cells do not rely on EGFR signaling to proliferate and
that cetuximab has no effect upon EGFR, HER2, AKT
and MAPK phosphorylation status, and even the
combination of cetuximab and the EGFR-specific tyro-
sine kinase inhibitor PD153035, did not display
enhanced toxicity when compared to either agent alone
[12]. Here, we observed that there was no significant dif-
ference in the proliferation of C33A cells treated with
LY294002 combined with matuzumab compared to
LY294002 treatment (P = 0.9076; Figures 5A and 5B),
neither there was a decrease in Akt phosphorylation eli-
cited by EGF in cells exposed to the combined treat-
ment (Figure 5C), when compared to LY294002. As
PI3K-Akt pathway activation leads to cell survival [4],
we evaluated whether the combination of matuzumab
and LY294002 was able to induce apoptosis, which
would explain the synergistic effect of these drugs
observed in A431 and CASKI cell lines. One of the ear-
liest features of apoptosis is the translocation of phos-
phatidylserine from the inner to the outer leaflet of the
plasma membrane. Apoptosis was measured by annexin
V staining, since annexin V binds to phosphatidylserine
exposed on the cell surface and identifies cells at an ear-
lier stage of apoptosis. In the A431 and CASKI cell
lines, but not in C33A cells, there was an increased
induction of apoptosis by combined treatment with
matuzumab and LY 294002 compared to isolated treat-
ments (Figure 5D). Altogether, these data corroborate
the hypothesis that resistance to matuzumab in EGFR
expressing cells, such as A431 and Caski, could be
modulated by agents that disrupt the persistent down-
stream signaling pathways observed here. PI3K pathway-
targeted therapies, which will ultimately lead to an effi-
cient blockade of Akt activation, may become promising
drugs to manage resistance to matuzumab in gynecolo-
gical oncology clinics.
Matuzumab induces ADCC in Caski cell line, but not in
C33A cells
ADCC is an important in vivo mechanism of cell-
mediated immunity whereby an effector cell of the
immune system actively lyses a target cell that has been
recognized by specific antibodies. It is one of the
mechanisms through which anti-EGFR antibodies can
act to limit and contain tumor growth. The ADCC phe-
nomenon is dependent on the number of EGFR mole-
cules per cell and how efficiently they are recognized by
antibodies [9,12,20]. FACS analysis showed that matuzu-
mab detected a larger amount of cell surface receptors
than the anti-EGFR antibody in A431 and Caski cells
(Figure 1A, P < 0.05). In C33A cells, matuzumab was
able to detect a small amount of EGFR molecules per
cell, but there was no substantial difference when com-
pared to the control (Figure 1A). Accordingly, at Effec-
tor/Target (E/T) ratio of 20:1, matuzumab mediated
lysis in 10.6% of Caski cells, but not in C33A cells
(3.1%) (Figure 5E). Thus, in spite of the lack of effects
Figure 4 Combination of matuzumab with PD98059, a MAPK
inhibitor, induces antagonistic effects in A431, Caski and C33A
cells. (A) Effects of combined treatment of matuzumab (100 μg/mL)
with a MAPK pathway inhibitor, PD98059 (25 μM), on cell viability
by MTT assay and (B) Western blotting analysis of phosphorylation
of p44/42 (ERK) 1/2 on Caski and C33A cells.
Meira et al. Molecular Cancer 2011, 10:151
http://www.molecular-cancer.com/content/10/1/151
Page 8 of 13upon EGFR signaling, ADCC induced by matuzumab is
dependent on cell surface expression of EGFR and this
event could account for its partial effectiveness in clini-
cal trials so far [21-23]
Discussion
In the last decades, research in cancer generated a major
progress in the understanding of the molecular basis of
cancer that, along with biotechnology advances, allowed
Figure 5 Targeting PI3K could overcome resistance to matuzumab. (A) Effects of combined treatment of matuzumab (100 μg/mL) with a
PI3K inhibitor, LY294002 (10 μM), on the colony formation of A431, Caski and C33A cells by clonogenic assay (CA). (B) Representative pictures of
colonies of A431, Caski and C33A cells after treatments with matuzumab (100 μg/mL) and/or LY294002 (10 μM) in CA and (C) WB analysis of
total and phosphorylated Akt (Ser 473) on A431, Caski and C33A cells. (D) Effects of combined treatment of matuzumab and LY 294002 on the
apoptosis of gynecological cancer cell lines analyzed by annexin V staining. (E) Cells were incubated alone or in the presence of 4 μg/mL of
matuzumab for 4 h and exposed to peripheral blood mononuclear cells (PBMCs, effector cells) at effector/target ratio (E/T) of 20:1 for more 4 h
and specific cytolysis (ADCC) was measured. Student’s t test * P < 0.05, when compared to control cells.
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and a subsequent improvement in cancer treatment.
Despite the progress, mechanisms of resistance to can-
cer therapy either inherited or acquired remain a hurdle,
requiring new strategies to overcome it. The anti-EGFR
MAb matuzumab was tested in early clinical trials in
some tumor types, even though the preclinical data sup-
porting its antitumor efficacy was scarce. The present
report, to the best of our knowledge, is the first one to
show that matuzumab does not synergize with chemora-
diation cytotoxic effects on gynecological cancer cell
l i n e s .A d d i t i o n a l l y ,w ew e r ea b l et os h o wt h a tt h el a c k
of efficacy may be attributed to an impaired mechanism
of EGFR down-regulation. Nonetheless, this relative
intrinsic resistance could be circumvented by the use of
PI3K inhibitors that may emerge as a novel target in
this tumor type.
In this study, we used a panel of gynecological cancer
cell lines, with different EGFR/HER2 status, that we
have previously characterized [12]. A431, a vulvar carci-
noma cell line, strongly expresses EGFR, while the cervi-
cal carcinoma Caski and C33A cell lines showed
moderate and low expression levels of this receptor [12].
Although bearing differences regarding EGFR expres-
sion, each one of these cell lines harbor genetic modifi-
cations that overactivate the EGFR pathway, as follows:
A431 has the EGFR gene amplified (30 copies) and
Caski cells harbor a PIK3CA exon 9 activating mutation
(E545K), while C33A has a PTEN mutation [24-26].
These genetic lesions assure that EGFR pathway signal-
ing is enhanced and, therefore, these cells behave as
constantly activated by EGF. Nonetheless, the resulting
signaling of such molecular alterations differs among
these cell lines (for example, the constitutive levels of
pAkt) and may differentially affect its response to PI3K/
Akt pathway modulation. However, EGF-elicited signal
transduction is not the only mechanism mediated by
anti-EGFR MAbs, since these molecules can also induce
ADCC [9] and, in primary cervical cancer cell lines
obtained from cervical biopsies, ADCC induction was
dependent on EGFR expression [20]. Accordingly, matu-
zumab effectively induced ADCC in A431 [13] and
Caski cells, while no ADCC was observed in the C33A
cell line, reinforcing that induction of ADCC depends
on a certain level of EGFR cell surface expression.
In our previous study, we demonstrated that although
A431, Caski and C33A showed different sensitivities to
RxT and cisplatin, all cell lines tested showed a clearly
improvement in cytotoxicity when anti-EGFR MAb
cetuximab was added to chemoradiation treatments
[12]. In the present study, we have shown that, unlikely
cetuximab [12], matuzumab fails to induce EGFR down-
regulation and chemo/radio sensitization. These precli-
nical findings might explain the overall unsuccessful
results obtained in phase I and II studies testing matu-
zumab. No evidence of clinical activity was observed
when matuzumab was administered as monotherapy in
patients with epithelial ovarian cancer [21] and, phase II
studies showed that matuzumab combined with epirubi-
cin, cisplatin and capecitabine (ECX), or pemetrexed,
does not increase response or survival of patients with
advanced esophagic-gastric and NSCLC cancers, respec-
tively [22,23]. Moreover, it was recently reported that
Takeda Pharmaceutical Company Limited discontinued
matuzumab development based on the negative clinical
findings to date [27].
It has been recently described that derailed endocyto-
sis is an emerging feature of cancer [28,29] and receptor
down-regulation induced by anti-EGFR MAbs was
described as an important mechanisms responsible for
growth factor receptors inactivation and termination of
EGFR cascade signaling [17,28-32]. Additionally, it has
been described that EGFR accumulation on the cell
membrane is responsible for cetuximab resistance in
NSCLC and head and neck carcinoma cells [8,31].
Importantly, it has been reported that EGFR internaliza-
tion/degradation is controlled by receptor dimerization,
rather than kinase activation [33]. Moreover, based on
structural studies, a model has been proposed in which
matuzumab binding to EGFR prevents the conforma-
tional rearrangement required for dimerization [34].
Our data corroborate all these observations, as we
described that matuzumab indeed reduced EGFR phos-
phorylation status, although it was not able to decrease
total EGFR protein content in gynecological cancer cells,
with consequent activation of downstream signaling
pathways and persistent cell proliferation. Described by
several authors [6-8,28-30,35-37], defective EGFR inter-
nalization/down-regulation also facilitates heterodimeri-
zation with other ErbB family members, with persistent
cell signaling and survival. Accordingly, we suggested
that efficient removal of EGFR from the cell surface
through the induction of receptor down-regulation by
MAbs is likely to reduce the oncogenic potential of the
receptor. According to this hypothesis, in a previous
study, we demonstrated that the use of cetuximab syner-
gized with matuzumab through the induction of EGFR
degradation and inhibition of downstream signaling
pathways in A431 cells [13]. Here, we have shown that
the lack of efficacy of matuzumab in monotherapy also
seems to correlate to its inability to induce EGFR degra-
dation, since proteassomal blockade in the presence of
matuzumab did not induce further EGFR accumulation
when compared to control. Furthermore, p-EGFR accu-
mulation under proteassomal inhibition led to ERK/
MAPK and Akt activation, corroborating the idea that
degradation of EGFR is directly associated to the termi-
nation of the signaling cascade. Interestingly, cetuximab
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suggesting that the EGFR degradation induced by this
MAb is indeed necessary to its downstream effects upon
PI3K/Akt pathway.
Activation of PI3K leads to plasma membrane recruit-
ment and activation of Akt, that has been found to be a
central cause of tumor-cell resistance and might have a
significant role in modulating the effectiveness of ErbB-
directed therapies [4,38]. Indeed, it is well known that
acceleration of internalization and lysosomal targeting
leads to EGFR down-regulation, which leads to a
decrease in the number of activated receptors in the
cell, preventing excessive signaling [28,29,32]. Impor-
tantly, activation of PI3K and protein kinase B (PKB)/
Akt is thought to occur mostly at the plasma membrane
compartment and is, therefore, negatively regulated by
endocytosis [39].
EGFR accumulation at plasma membrane enhances
the recruitment and activation of PKB/Akt proteins, and
these events could be responsible for maintaining cell
proliferation and survival. In the present study, the
importance of the PI3K/Akt pathway in modulating the
resistance to matuzumab in A431 and Caski cells was
demonstrated when we combined LY294002, a specific
PI3K inhibitor, which resulted in a synergistic inhibition
of cell signaling, proliferation and apoptosis induction.
Akt modulates cell signaling by phosphorylation of sev-
eral substrates and among them is caspase-9, a protease
that is activated in the apoptotic cell death pathway.
Akt-phosphorylated caspase-9 is inactive and not able to
trigger caspase-3 cleavage and its subsequent activation,
leading to cell death blockade [5]. Here, we show that
the combination of matuzumab and a PI3K inhibitor is
able to induce cell death by apoptosis, suggesting that
impairment of PI3K signaling releases the negative regu-
lation exerted by this kinase upon the apoptotic
machinery.
Recently, it was described that PTEN gene is mutated
in C33A cells [26] and loss of PTEN protein expression
induces Akt constitutive activation and proliferation of
C33A cells [40]. Accordingly, in our previous study, we
have shown that C33A cells expressed higher constitu-
tive levels of p-Akt, when compared to A431 and Caski
cells [12]. These findings may explain why LY294002
alone induced a markedly reduction in C33A cell survi-
val, with no additional inhibition reached by matuzumab
double treatment, since EGFR expression is almost
undetectable in this cell line [12], suggesting that C33A
cell survival is driven in a great extent by Akt signaling,
in an EGFR-independent manner. Importantly, human
papillomavirus (HPV) infection represents the most rele-
vant risk factor for the development of cervical cancer
[20]. Indeed, recently it was described that activation of
the PI3-kinase/PKB/AKT pathway through the active
subunit phosphatidylinositol 3-kinase catalytic alpha
(PIK3CA) is essential for HPV-induced transformation
in vitro [41]. Caski cells are HPV positive, and also har-
bor an activating mutation in the PIK3CA gene [25].
This cell line constitutes a pre-clinical model that repre-
sents a broad spectrum of HPV positive cervical cancer
patients that, according to our results, could benefit by
a combination of anti-EGFR based therapies and PI3K-
Akt inhibitors.
Based on these findings, we proposed a model (Figure 6)
that explains one possible mechanism of ineffectiveness of
matuzumab and how to overcome it. Matuzumab, differ-
ently from cetuximab, was not able to induce EGFR
down-regulation, with persistent signaling and gyneco-
logical cancer cell proliferation (Figure 6A). Although
the combination of matuzumab with chemoradiation
or a MAPK pathway inhibitor did not trigger benefits
over single treatments (Figure 6B), we observed that tar-
geting PI3K, in combination with matuzumab, markedly
reduced A431 and Caski cell survival, highlighting the
importance of PI3K/Akt pathway (Figure 6C).
The present report is the first one to bring out precli-
nical studies showing matuzumab resistance in vitro in
gynecological cancer cell lines and highlights that
impaired EGFR down-regulation might be the possible
biological mechanism responsible for its inefficacy. Even
though the majority of gynecological cancers express
EGFR [42], these tumors are not solely dependent upon
EGFR activity. This is likely due to the presence of pre-
existing or treatment-induced compensatory signaling
pathways. Since EGFR signaling involves intracellular
interactions with other oncogenic pathways, it is plausi-
ble that cotargeting of EGFR in rational combination
with specific inhibitors of these pathways may achieve a
more potent antitumour effect and help to overcome
the development of resistance, an emerging clinical issue
often responsible for the failure of most modern antitu-
mour approaches. These results indicate that Akt path-
way and EGFR may not be completely responsible, but
cooperate in the resistance of gynecological cancer cells
to matuzumab and suggest a rationale for the design of
clinical strategies directed to patients displaying a resis-
tant profile to anti-EGFR therapies. Our results, along
with the knowledge that different signal transduction
pathways controls tumor growth and are connected to
resistance, suggest that future therapeutic approaches
are likely to involve the combination of different anti-
neoplastic targeted agents.
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